Puerto Rican plant to boost US supplies of heparin
This article was originally published in Scrip
Executive Summary
US FDAapproval for APP Pharmaceuticals's Puerto Rican plant to manufacture three heparin products should help ensure the uninterrupted and safe supply of heparin to the US, says the company. APP is currently the sole supplier of therapeutic heparin vials to the US after contamination problems occurred there earlier this year, says the company's CEO, Tom Silberg. Nine products are currently manufactured at the company's Puerto Rican plant, including doxycycline, azithromycin and diphenhydramine.
You may also be interested in...
WHO Launches Action Plan For Cross-Country Market Access Collaborations
While information sharing is key to cross-country collaborations on access to medicines and can lead to major benefits, it is hard to sell to political leaders and the media, says a report from the World Health Organization’s regional office for Europe.
EU Orphan Law Under Attack Over ‘Flawed Incentives’
The European Commission says it will publish its review of the EU orphan drug legislation in the coming days.
UK Pulls Out Of Unified Patent Court Agreement
The UK has formally withdrawn its ratification of the Unified Patent Court Agreement, adding to the uncertainty over its future.
Need a specific report? 1000+ reports available
Buy Reports